353 related articles for article (PubMed ID: 29187446)
1.
Na K; Sung JY; Kim HS
Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
[TBL] [Abstract][Full Text] [Related]
2. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
3. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
Kim HN; Woo HY; DO SI; Kim HS
In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM
J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
[TBL] [Abstract][Full Text] [Related]
6. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
7. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
[TBL] [Abstract][Full Text] [Related]
8. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
[TBL] [Abstract][Full Text] [Related]
9. Cardiophrenic Lymph Node Metastasis of Ovarian High-grade Serous Carcinoma Showing Wild-type p53 Immunostaining Pattern and Aberrant CD56 Expression.
Kwon HJ; Oh M; Han J; Song SY; Kim HS
Int J Surg Pathol; 2021 Dec; 29(8):864-869. PubMed ID: 33764173
[TBL] [Abstract][Full Text] [Related]
10. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
[TBL] [Abstract][Full Text] [Related]
11. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
[TBL] [Abstract][Full Text] [Related]
12. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
[TBL] [Abstract][Full Text] [Related]
13. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
14. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
Holý P; Hlaváč V; Šeborová K; Šůsová S; Tesařová T; Rob L; Hruda M; Bouda J; Bartáková A; Mrhalová M; Kopečková K; Al Obeed Allah M; Špaček J; Sedláková I; Souček P; Václavíková R
Int J Cancer; 2024 Jul; 155(1):104-116. PubMed ID: 38447012
[TBL] [Abstract][Full Text] [Related]
15. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
16. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
[TBL] [Abstract][Full Text] [Related]
17. Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.
Ardighieri L; Mori L; Conzadori S; Bugatti M; Falchetti M; Donzelli CM; Ravaggi A; Odicino FE; Facchetti F
Virchows Arch; 2016 Jul; 469(1):61-9. PubMed ID: 27059324
[TBL] [Abstract][Full Text] [Related]
18. High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis.
Hatano Y; Fukuda S; Makino H; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2018 Apr; 13(1):24. PubMed ID: 29703236
[TBL] [Abstract][Full Text] [Related]
19. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.
Kim J; Coffey DM; Ma L; Matzuk MM
Endocrinology; 2015 Jun; 156(6):1975-81. PubMed ID: 25815421
[TBL] [Abstract][Full Text] [Related]
20. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
